急性髓系白血病靶向治疗的研究进展  

Research progress of targeted therapy for acute myeloid leukemia

作　　者：龙心怡 胡荣[1] LONG Xinyi;HU Rong(Department of Hematology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110000,China.)

机构地区：[1]中国医科大学附属盛京医院第一血液科,辽宁沈阳110000

出　　处：《现代肿瘤医学》2022年第15期2847-2850,共4页Journal of Modern Oncology

基　　金：辽宁省教育厅科学研究经费项目(编号:JC2019011)。

摘　　要：近年来,治疗急性髓系白血病(acute myeloid leukemia,AML)的新药层出不穷,目前已经有几种新的靶向药物获得FDA批准。本文综述了包括针对FLT3信号通路的靶向药物、针对CD33抗原的靶向药物、针对BCL-2基因的靶向药物、针对IDH基因的靶向药物、针对免疫检查点的靶向药物以及CPX-351等药物的作用机制及临床研究进展,为AML未来治疗选择的扩大化、精准化和个性化提供了思路。For the past few years,there have been an increasing number of novel agents identified for treatment in AML(acute myeloid leukemia).Several new targeted agents have been approved by the FDA,including FLT3 inhibitors,CD33-targeted therapy,venetoclax,IDH inhibitors,immune checkpoint inhibitiors,CPX-351 and so on.This review summarizes the mechanisms of drug action and the progresses of clinical researches,which provides hope that future treatment choices will become increasingly expanded,precise and personalized.

关 键 词：急性髓系白血病 靶向药物 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]